A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Weight Management

In brief

This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adults living with obesity or overweight with at least one weight-related comorbidity, and without T2DM (Study 1) or with T2DM (Study 2).

Key facts

Study ID

NCT07667803

Run by

AstraZeneca

People needed

4500

Starts

2026-06-29

Expected to finish

2029-07-30

Last updated by the study team

2026-07-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Legal age of consent and at least 18 years old
• Study 1 -
• BMI ≥ 30 kg/m2 or
• 25 kg/m2 ≤ BMI < 30 kg/m2 with at least one of the following weight-related comorbidities:
• Hypertension
• Prediabetes
• Dyslipidemia
• Cardiovascular disease
• Obstructive sleep apnea.
• Study 2 - BMI ≥ 25 kg/m2 and T2DM defined as below:
• Established diagnosis of T2DM
• Without established diagnosis of T2DM and HbA1c ≥ 6.5% (48 mmol/mol) at the screening visit
• Stable body weight (self-reported or documented) for 90 days prior to the screening visit (± 5% body weight change)
• History of at least one self-reported unsuccessful dietary effort to lose body weight.

You may not qualify if…

• Study 1 - Established diagnosis of T1DM or T2DM.
• Study 2 - Any of the following medical history, laboratory values, or complications related to diabetes:
• T1DM
• HbA1c ≥ 10% (86 mmol/mol) at the screening visit
• Currently receiving, or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema.
• Have had more than one episode of severe hypoglycemia within 180 days prior to the screening visit, or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
• History of acute (unless due to previously resolved gallstone pancreatitis and post-cholecystectomy) or chronic pancreatitis
• History/family history (first degree biologic relatives) of medullary thyroid cancer or multiple endocrine neoplasia type 2

Where it is running

• Research Site — Truro, Nova Scotia, Canada (enrolling)
• Research Site — Toronto, Ontario, Canada (enrolling)
• Research Site — Taichung, Taiwan (enrolling)
• Research Site — St Albans, Australia (enrolling)
• Research Site — Leicester, United Kingdom (enrolling)
• Research Site — Rolling Hills Estates, California, United States
• Research Site — Lynwood, California, United States
• Research Site — Chandler, Arizona, United States
• Research Site — Clearwater, Florida, United States
• Research Site — New Haven, Connecticut, United States
• Research Site — Plantation, Florida, United States
• Research Site — Woodstock, Georgia, United States
• Research Site — Ammon, Idaho, United States
• Research Site — Melrose Park, Illinois, United States
• Research Site — Little Rock, Arkansas, United States
• Research Site — Alexandria, Louisiana, United States
• Research Site — Louisville, Kentucky, United States
• Research Site — Arvada, Colorado, United States
• Research Site — Baltimore, Maryland, United States
• Research Site — Potomac, Maryland, United States
• Research Site — White Marsh, Maryland, United States
• Research Site — Ypsilanti, Michigan, United States
• Research Site — Ridgeland, Mississippi, United States
• Research Site — Kansas City, Missouri, United States
• Research Site — Wichita, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.